JP2014523421A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523421A5
JP2014523421A5 JP2014516039A JP2014516039A JP2014523421A5 JP 2014523421 A5 JP2014523421 A5 JP 2014523421A5 JP 2014516039 A JP2014516039 A JP 2014516039A JP 2014516039 A JP2014516039 A JP 2014516039A JP 2014523421 A5 JP2014523421 A5 JP 2014523421A5
Authority
JP
Japan
Prior art keywords
dll4
formulation
ionizing radiation
cancer
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014516039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523421A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042695 external-priority patent/WO2012174394A1/en
Publication of JP2014523421A publication Critical patent/JP2014523421A/ja
Publication of JP2014523421A5 publication Critical patent/JP2014523421A5/ja
Ceased legal-status Critical Current

Links

JP2014516039A 2011-06-17 2012-06-15 抗ｄｌｌ４抗体を使用して腫瘍治療における放射線に対する反応を増大させる方法 Ceased JP2014523421A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498200P 2011-06-17 2011-06-17
US61/498,200 2011-06-17
PCT/US2012/042695 WO2012174394A1 (en) 2011-06-17 2012-06-15 Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies

Publications (2)

Publication Number Publication Date
JP2014523421A JP2014523421A (ja) 2014-09-11
JP2014523421A5 true JP2014523421A5 (enExample) 2015-08-06

Family

ID=46397640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516039A Ceased JP2014523421A (ja) 2011-06-17 2012-06-15 抗ｄｌｌ４抗体を使用して腫瘍治療における放射線に対する反応を増大させる方法

Country Status (6)

Country Link
US (1) US8685401B2 (enExample)
EP (1) EP2721070A1 (enExample)
JP (1) JP2014523421A (enExample)
AU (1) AU2012271450A1 (enExample)
CA (1) CA2838973A1 (enExample)
WO (1) WO2012174394A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201818814T4 (tr) 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
PT3485903T (pt) 2011-09-23 2023-02-17 Mereo Biopharma 5 Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
TWI830700B (zh) * 2017-06-12 2024-02-01 法商施維雅藥廠 以組合療法治療腦瘤之方法
EP3638236A1 (en) * 2017-06-12 2020-04-22 Agios Pharmaceuticals, Inc. Methods of treating brain tumors using combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
SI2066694T1 (sl) * 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za diagnosticiranje in zdravljenje raka
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
US20110059114A1 (en) 2009-08-05 2011-03-10 Duke University Compositions and Methods for the Treatment of Radioresistant Glioma Stem Cells
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Similar Documents

Publication Publication Date Title
AU2013327116B2 (en) Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer
JP2019527706A5 (enExample)
MX2020006042A (es) Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas.
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
HRP20211346T1 (hr) Kombinirani pripravci za liječenje raka
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
JP2018508512A5 (enExample)
IL292193B1 (en) Anti-b7-h1 antibodies for treating tumors
RU2014138040A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2019106663A (ru) Комбинированная терапия рака
JP2014523421A5 (enExample)
IL278423B2 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
MX2017012965A (es) Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo.
MX2016008362A (es) Combinaciones farmaceuticas.
JP2018518454A5 (enExample)
RU2014138041A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2017506217A5 (enExample)
JP2015532292A5 (enExample)
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
JP2017524715A5 (enExample)
JP2014530215A5 (enExample)
JP2018515137A5 (enExample)
JP2020502271A5 (enExample)
EA201000127A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака